AbbVie Inc.

Industry

  • Pharmaceuticals
    • Specialty Pharmaceuticals

Other Names/Subsidiaries

  • Aliada Therapeutics
  • Allergan
  • Celsius Therapeutics
  • Cerevel Therapeutics Holdings
  • DJS Antibodies
  • ImmunoGen
  • Luminera
  • Nimble Therapeutics
  • Mavupharma
  • Mitokinin
  • Pharmacyclics
  • Stemcentrx
  • Syndesi Therapeutics
See more in Biomedtracker

Latest on AbbVie Inc.

Scrip

AbbVie Increases US Manufacturing, But Says It’s Not Because Of Tariffs

 
• By Joseph Haas

During its first quarter sales and earnings call on 25 April, AbbVie CEO Robert Michael expressed confidence that the company can weather the current tariffs introduced by the Trump Administration as

Scrip

Galapagos Chief Exec Stoffels Leaving, While Firm Names Spinout’s CEO

 
• By Mandy Jackson

Galapagos revealed its second leadership transition in as many weeks on 22 April, reporting that CEO Paul Stoffels plans to retire from the company upon the appointment of a new chief executive, who w

Generics Bulletin

Samsung Bioepis Reevaluating Approach To Biosimilars

 
• By Jessica Merrill

Samsung Bioepis has been a pioneer in the US biosimilar market since its first biosimilar Renflexis (infliximab-abda) was approved by the US Food and Drug Administration in 2017, but expensive develop

Scrip

Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 
• By Eleanor Malone

Strong growth across multiple cancer indications as well as price rises saw Merck & Co’s PD-1 inhibitor Keytruda (pembrolizumab) increase its revenues by 18% in 2024, putting it more than $12bn ah